Skip to main content

Advertisement

Springer Nature Link
Log in

Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Follicular Lymphoma International Prognostic Index—FLIPI is an established clinical predictor for outcome in follicular lymphoma. The role of molecular abnormalities in blood and bone marrow of follicular lymphoma patients including t(14;18) is less clear. Seventy-five patients from a single institution diagnosed with follicular lymphoma between1999 and 2005 were included into the study. Diagnosis was based on lymph node biopsy in 62 cases (83%). Thirty-nine patients (52%) had G1 histological grade and 47 (63%) had entirely follicular growth pattern, as well as 9 patients (12%) had systemic symptoms and 33 (44%) were assigned to a good risk according to FLIPI. Median age of patients was 53 years. During a median observation time of 3 years 63 patients (84%) required initiating anti-lymphoma treatment. Seventy-five samples of peripheral blood and 65 samples of bone marrow were collected at the diagnosis. Bcl2 rearrangements including major breakpoint region and minor breakpoint cluster region were investigated using nested polymerase chain reaction technique. The primary end points of the study were time to first line lymphoma treatment and progression-free survival. Cells carrying t(14;18) were found in 31 cases (41%) including 29 samples of peripheral blood and 26 samples of bone marrow. Detection of t(14;18) in blood and bone marrow at diagnosis had no influence on clinical outcome. Age, follicular growth pattern systemic symptoms, and FLIPI score above 1 were predictive for initiation of the first lymphoma therapy. Follicular growth pattern, initial nodal involvement, serum LDH level, and FLIPI score above 1 were predictive for longer progression-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. In: Kleihues P, Sobin L, editors. World Health Organization classification of tumors. vol. 3. Lyon: IARC Press; 2001.

    Google Scholar 

  2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–95.

    PubMed  CAS  Google Scholar 

  3. Buchonnet G, et al. Characterization of Bcl2-JH rearrangement in follicular lymphoma: PCR detection of 3’ Bcl2 breakpoints and evidence of new cluster. Leukemia 2000;14:1563–9.

    Article  PubMed  CAS  Google Scholar 

  4. Jaeger U, et al. Molecular mechanism of the t(14,18)—a model for lymphoid-specific chromosomal translocations. Leuk Lymphoma. 1994;14:197–202.

    Article  PubMed  CAS  Google Scholar 

  5. Mrózek K, Bloomfield CD. Cytogenetics of Indolent Lymphomas. Semin Oncol. 1993;20(Suppl 5):47–57.

    PubMed  Google Scholar 

  6. Aster J, Longtine J. Detection of Bcl2 rearrangements in follicular lymphoma. Am J Pathol. 2002;160:759–63.

    PubMed  CAS  Google Scholar 

  7. Voutsadakis IA. Apoptosis and pathogenesis of lymphoma. Acta Oncol. 2000;39:151–6.

    Article  PubMed  CAS  Google Scholar 

  8. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  9. Solal-Celigny P, et al. Follicular lymphoma international index. Blood 2004;104:1258–65.

    Article  PubMed  CAS  Google Scholar 

  10. Maniatis T, et al. Molecular cloning: a laboratory manual. CSH Laboratory Press; 1982.

  11. Gribben JG, et al. All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 1991;78:3275–80.

    PubMed  CAS  Google Scholar 

  12. Cheson B, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244–53.

    PubMed  CAS  Google Scholar 

  13. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84:1–12.

    Article  PubMed  Google Scholar 

  14. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis from geographic variation. Blood. 2002;99:4265–75.

    Article  PubMed  CAS  Google Scholar 

  15. Wojciechowska U, Didkowska J, Tarkowski W, Zatonski W. Cancer in Poland in 2005. http://epid.coi.waw.pl/krn.

  16. Galazka K, Szpor J, Maryniak R, et al. Incidence of lymphomas in Poland. The National Register Data for 2006. Pol J Pathol. 2007;58:199–206.

    PubMed  Google Scholar 

  17. Aster JC, Longtine JA. Detection of Bcl2 rearrangements in follicular lymphoma. Am J Pathol. 2002;160:759–63.

    PubMed  CAS  Google Scholar 

  18. van Dongen JJM, et al. Design of standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.

    Article  PubMed  Google Scholar 

  19. Johnson PWM, et al. Variability of polymerase chain reaction detection of bcl-2-Igh translocation in an international multicentre study. Ann Oncol. 1999;10:1349–54.

    Article  PubMed  CAS  Google Scholar 

  20. Bagg A, Braziel RM, Arber DA, Bijwaard KE, Chu AY. Immunoglobulin heavy chain gene analisis in lymphomas. A multi-center study demonstrating the heterogenity of performance of polymerase chain reaction assays. J Mol Diagn. 2002;4:81–9.

    PubMed  CAS  Google Scholar 

  21. Liu J, Johson RM, Traweek ST. Rearrangement of BCL-2 gene in follicular lymphoma. Detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol. 1993;2:241–7.

    PubMed  CAS  Google Scholar 

  22. Albinger-Hegyi A, et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas. Improved polymerase chain reaction protocols for their detection. Am J Pathol. 2002;160:823–32.

    PubMed  CAS  Google Scholar 

  23. James A, et al. Follicular lymphoma with novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells. Blood. 2002;15:716–8.

    Google Scholar 

  24. Lubinski J, et al. Environmental factors may regulate BCL2 associated lymphomagenesis: a very low incidence of BCL2-MBR translocation in Poland. Pol J Pathol. 1995;46:219–24.

    PubMed  CAS  Google Scholar 

  25. Dölken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangement in circulating B cells of healthy blood donors and patients with non-malignant diseases. J Clin Oncol. 1996;14:1333–44.

    PubMed  Google Scholar 

  26. Summers K, et al. Frequency of the BCL-2/JH rearrangement in normal individuals: implication for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol. 2001;19:420–4.

    PubMed  CAS  Google Scholar 

  27. McGregor D, et al. The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells. Bone Marrow Transplant. 2005;35:1049–54.

    Article  PubMed  CAS  Google Scholar 

  28. Sehn LH, Gascoyne RD, Connors JM, Klasa RJ, Horsman DE. Comparison of t(14;18) positive and t(14;18) negative follicular lymphoma (FL): clinical characteristics, outcomes and cytogenetics. Blood. 2000;96:574.

    Google Scholar 

  29. Lopez-Guillermo A, et al. Correlation of BCL-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphomas. Blood. 1999;91:2955–60.

    Google Scholar 

  30. Iqubal S, et al. Reliable detection of clonal IgH/BCL2 MBR rearrangements in follicular lymphoma: methodology and clinical significance. Br J Haematol. 2004;124:325–8.

    Article  Google Scholar 

  31. Montoto S, et al. Incidence and clinical significance of BCL-2/IgH rearrangements in follicular lymphoma. Leuk Lymphoma. 2003:44:71–6.

    Article  PubMed  Google Scholar 

  32. Gascoyne RD, et al. Prognostic significance of BCL 2 protein expression and BCL 2 gene rearrangements in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.

    PubMed  CAS  Google Scholar 

  33. Barrans SL, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9:2133–39.

    PubMed  CAS  Google Scholar 

  34. Goodlad JR, et al. BCL2 gene abnormalities define distinct clinical subsets of follicular lymphoma. Histopathology 2006;49:229–41.

    Article  PubMed  CAS  Google Scholar 

  35. Franco R, et al. Cutaneous follicular B-cell lymphoma: description of a series of 18 cases. Am J Surg Pathol. 2001;25:875–83.

    Article  PubMed  CAS  Google Scholar 

  36. Lopez-Guillermo A, et al. The significance of molecular response in indolent follicular lymphomas. Blood. 1998;91:2955–60.

    PubMed  CAS  Google Scholar 

  37. Finke J, Slanina J, Lange W, Dölken G. Persistence of circulating t(14;18)-positive cells in long term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol. 1993;11:1668–73.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoproliferative Diseases, The Maria Sklodowska-Curie Memorial Institute and Cancer Centre, 5 Roentgen Str., 02-781, Warsaw, Poland

    E. Paszkiewicz-Kozik & J. Walewski

  2. Department of Molecular Biology, The Maria Sklodowska-Curie Memorial Institute and Cancer Centre, 5 Roentgen Str., 02-781, Warsaw, Poland

    J. Kulik, A. Fabisiewicz, A. Tysarowski & J. A. Siedlecki

  3. Department of Biostatistics, The Maria Sklodowska-Curie Memorial Institute and Cancer Centre, 5 Roentgen Str., 02-781, Warsaw, Poland

    E. Kraszewska

Authors
  1. E. Paszkiewicz-Kozik
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. J. Kulik
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. A. Fabisiewicz
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. A. Tysarowski
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. E. Kraszewska
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. J. A. Siedlecki
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. J. Walewski
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to E. Paszkiewicz-Kozik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paszkiewicz-Kozik, E., Kulik, J., Fabisiewicz, A. et al. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma. Med Oncol 26, 16–21 (2009). https://doi.org/10.1007/s12032-008-9071-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-008-9071-1

Keywords